Syngene International reported a 56% year-on-year decline in consolidated operating EBITDA to ₹91 crore for the quarter ended June 30, 2026, as severe foreign exchange losses and weak biologics demand weighed on performance. Revenue from operations contracted 16% to ₹736 crore, while profit after tax (PAT) before exceptional items plummeted 99% to ₹1 crore. The company’s net loss widened to ₹90 crore after accounting for ₹100 million in exceptional termination benefits. Executive Chairperson Kiran Mazumdar-Shaw and new Managing Director Siddharth Mittal outlined a strategic pivot toward CDMO and AI-led services to restore growth momentum.

The Board of Directors approved the unaudited financial results on July 29, 2026, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The financial statements were prepared under Indian Accounting Standards (Ind AS) and subjected to a limited review by statutory auditor B S R & Co. LLP. The audit committee reviewed the statements on July 28, 2026.

Financial Performance Overview

Consolidated revenue from operations declined to ₹7,360 million from ₹8,745 million in Q1FY26. Total income decreased to ₹7,613 million from ₹8,922 million. Operating EBITDA margin compressed sharply to 12.34% from 23.60% in the prior year period. The following table details the key financial metrics:

Standalone revenue fell 17% to ₹6,630 million. Standalone net loss widened to ₹21 million from a profit of ₹740 million in Q1FY26. Total expenses decreased to ₹7,670 million from ₹7,909 million, driven by a 20% drop in material costs to ₹1,734 million and a 4% reduction in staff costs to ₹2,814 million. However, these savings were insufficient to offset the revenue decline and currency headwinds.

Key Loss Drivers and Exceptional Items

The primary drag on profitability was a foreign exchange fluctuation loss of ₹501 million, compared to a loss of just ₹48 million in Q1FY26. Chief Financial Officer Deepak Jain attributed the performance impact to the "lack of offtake from a major biologics client" alongside the forex hedge loss. Additionally, the company recognized ₹100 million (net of tax) as an exceptional item related to termination benefits extended to employees in accordance with approved policy. This follows earlier adjustments for gratuity obligations linked to the new Labour Codes notified by the Government of India in November 2025.

Other income increased 43% to ₹253 million from ₹177 million in the previous year’s quarter. The company capitalized ₹293 million under capital work in progress during the quarter, relating to pre-operating costs for its biologics manufacturing facility acquired from Emergent Manufacturing Operations Baltimore, LLC. This facility is expected to increase single-use bioreactor capacity to 50,000L.

Leadership Changes and Strategic Outlook

Kiran Mazumdar-Shaw accepted the role of Executive Chairperson, emphasizing a focus on CDMO and AI-led advanced services. Siddharth Mittal, appointed as Managing Director and CEO, stated his immediate priorities are sharpening commercial execution and building a cost-competitive organization. The Board also appointed Dr. Vijaya Chandru and Dr. Arun Chandavarkar as Independent Directors, while Dr. Kush Parmar stepped down.

Syngene signed a Memorandum of Understanding with BRIC-Translational Health Science and Technology Institute (THSTI) for early and late-phase clinical development. The company also advanced its Syn.AI platform, developing gigascale virtual screening capabilities. Management expects business momentum to improve in the second half of FY27, targeting single-digit revenue degrowth and mid-20s EBITDA margins for the full year.

What the Numbers Show

The divergence between operational cost discipline and bottom-line erosion highlights Syngene’s acute sensitivity to currency volatility and client concentration. While material and staff costs declined by 20% and 4% respectively, the ₹501 million forex loss alone exceeded the entire PAT from Q1FY26. The compression of EBITDA margins from 23.60% to 12.34% underscores the challenge of maintaining profitability amid headwinds in the biologics segment. The strategic pivot toward AI and CDMO services aims to diversify revenue streams, but near-term results remain constrained by the delayed offtake from key clients.

Syngene International Limited will host a conference call on July 30, 2026, to discuss its financial results for the quarter ended June 2026. The earnings call, scheduled from 9:00 AM to 10:00 AM IST, will provide analysts and investors with an overview of the company's performance in Q1 FY2027. The session will begin with a brief management discussion followed by an interactive Question & Answer session. Participants can join the discussion via dial-in numbers or a webcast link, and a pre-registration facility has been provided to streamline the connection process for attendees.

Conference Call Details

The following dial-in numbers and access details have been made available for participants across geographies:

Access and Replay Options

Participants can join the webcast directly via the provided link. For those unable to attend the live session, a replay facility will be available. The audio replay can be accessed by dialing +91 22 71945757 and using Playback ID 48209#. This facility will be accessible from July 30, 2026, until August 5, 2026. Additionally, the audio recording and a transcript of the conference call will be made available on the corporate website within seven working days of the event.

Syngene International Ltd. is an integrated research, development, and manufacturing services company serving the global pharmaceutical, biotechnology, and specialty chemical sectors. The company operates over 3 million sq. ft of specialized facilities across India and the U.S.